Literature DB >> 7847420

Biorhythms and chronotherapy in cardiovascular disease.

H M Cooke1, A Lynch.   

Abstract

Recent findings about the effects of biorhythms on cardiovascular disorders are reviewed, and their implications for drug therapy are discussed. The chronobiological approach to physiology evaluates time-dependent changes in biological functions and considers those changes to be multifactorial. Characterization of disease states with this approach allows more accurate determination of the times when patients are at highest risk and therefore in greatest need of preventive measures; it also provides a mechanism for designing optimal drug regimens. There is evidence of circadian variations in the occurrence of myocardial ischemia, acute myocardial infarction, ventricular tachycardia, and sudden cardiac death. Many cardiovascular disorders occur with greatest frequency between 0600 and 1200 in the general population. Blood pressure, too, follows a distinct circadian pattern. Factors affecting circadian variations in cardiovascular disorders include physiological determinants, such as heart rate, catecholamine release, and platelet aggregation--which themselves vary cyclically--and exogenous factors, such as mental stress, anxiety, and physical activity. In chronotherapy, circadian variations in disease states and in the pharmacodynamic properties of drugs are exploited to improve prevention and treatment. Conditions in which research suggests a chronotherapeutic approach may be advantageous include thromboembolism, hypertension, stable exertional angina, variant angina, sustained ventricular tachycardia, and acute myocardial infarction. Information on circadian patterns in the occurrence of many cardiovascular disorders is enabling clinicians to tailor treatment in ways that may lead to improved patient outcomes.

Entities:  

Mesh:

Year:  1994        PMID: 7847420

Source DB:  PubMed          Journal:  Am J Hosp Pharm        ISSN: 0002-9289


  5 in total

Review 1.  Chronotherapy versus conventional statins therapy for the treatment of hyperlipidaemia.

Authors:  Jose Manuel Izquierdo-Palomares; Jesus Maria Fernandez-Tabera; Maria N Plana; Almudena Añino Alba; Pablo Gómez Álvarez; Inmaculada Fernandez-Esteban; Luis Carlos Saiz; Pilar Martin-Carrillo; Óscar Pinar López
Journal:  Cochrane Database Syst Rev       Date:  2016-11-26

2.  Comparison of telmisartan vs. valsartan in the treatment of mild to moderate hypertension using ambulatory blood pressure monitoring.

Authors:  George Bakris
Journal:  J Clin Hypertens (Greenwich)       Date:  2002 Jul-Aug       Impact factor: 3.738

Review 3.  Evening versus morning dosing regimen drug therapy for hypertension.

Authors:  Ping Zhao; Ping Xu; Chaomin Wan; Zhengrong Wang
Journal:  Cochrane Database Syst Rev       Date:  2011-10-05

4.  Chronobiology impacts response to antihypertensive drug regimen in type 2 diabetes.

Authors:  Eli A Friedman; Mary Ann Banerji
Journal:  Diabetes Care       Date:  2011-06       Impact factor: 19.112

5.  Acute restraint stress modifies the heart rate biorhythm in the poststress period.

Authors:  Eva Varejkova; Katerina Janisova; Jaromir Myslivecek
Journal:  Sci Rep       Date:  2019-02-11       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.